東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Pharmaceutical prices in the 21st ce...

Babar, Zaheer-Ud-Din.

FindBook

Google Book

Amazon

博客來

Pharmaceutical prices in the 21st century

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Pharmaceutical prices in the 21st century/ edited by Zaheer-Ud-Din Babar.
其他作者:	Babar, Zaheer-Ud-Din.
出版者:	Cham :Springer International Publishing : : 2015.,
面頁冊數:	x, 411 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Drugs - Prices. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-12169-7
ISBN:	9783319121697 (electronic bk.)

Pharmaceutical prices in the 21st century
Pharmaceutical prices in the 21st century[electronic resource] /edited by Zaheer-Ud-Din Babar. - Cham :Springer International Publishing :2015. - x, 411 p. :ill., digital ;24 cm.

The book is an essential, comprehensive text onglobal drug pricing and covers a range of pharmaceutical pricing issues. It has twenty-two chapters in total;nineteenof which are case studieson an array of high, middle, and low income countries. The final three chaptersdiscussvalue-based pricing, innovation, prices and the pharmaceutical industry and the link betweenpharmaceutical policy and pricing. As the pharmaceutical market continues to expand, a number of pharmaceutical pricing strategies have been employed to control drug expenditures. The book explores this phenomenon further and willserve a valuable resource for policy makers, funders, social insurance institutions and drug companies. About the author Zaheer-Ud-Din Babar, PhD is the Head of Pharmacy Practice at the School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. A pharmacist by training and a PhD in pharmaceutical policy, Dr Babar is a recipient of the prestigious Research Excellence Award from the University of Auckland. His research program covers areas related to pharmaceutical policy and practice, encompassing access to and affordability of medicines, issues related to medicine pricing and pharmacoeconomics. Dr Babar has delivered invited lectures at Boston University School of Public Health, Harvard Medical School, the Austrian Health Institute and the Universities of Reading and Kingston. He has also acted as a consultant for the World Health Organization, Health Action International, the International Union against Tuberculosis and Lung Disease, the International Pharmaceutical Federation (FIP) and the Pharmaceutical Management Agency of New Zealand in the area of medicines pricing and policies. Dr Babar is the Editor in Chief of the Journal of Pharmaceutical Policy and Practice, www.joppp.org and can be reached at z.babar@auckland.ac.nz.

ISBN: 9783319121697 (electronic bk.)

Standard No.: 10.1007/978-3-319-12169-7doiSubjects--Topical Terms:

821594
Drugs
--Prices.

LC Class. No.: HD9665.4

Dewey Class. No.: 338.436151

Pharmaceutical prices in the 21st century
LDR:02797nmm a2200301 a 4500 001 1994450
003 DE-He213
005 20150730113551.0
006 m d
007 cr nn 008maaau
008 151019s2015 gw s 0 eng d
020 $a 9783319121697 (electronic bk.)
020 $a 9783319121680 (paper)
024 7 $a 10.1007/978-3-319-12169-7 $2 doi
035 $a 978-3-319-12169-7
040 $a GP $c GP
041 0 $a eng
050 4 $a HD9665.4
072 7 $a KCQ $2 bicssc
072 7 $a BUS069000 $2 bisacsh
082 0 4 $a 338.436151 $2 23
090 $a HD9665.4 $b .P536 2015
245 0 0 $a Pharmaceutical prices in the 21st century $h [electronic resource] / $c edited by Zaheer-Ud-Din Babar.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a x, 411 p. : $b ill., digital ; $c 24 cm.
520 $a The book is an essential, comprehensive text onglobal drug pricing and covers a range of pharmaceutical pricing issues. It has twenty-two chapters in total;nineteenof which are case studieson an array of high, middle, and low income countries. The final three chaptersdiscussvalue-based pricing, innovation, prices and the pharmaceutical industry and the link betweenpharmaceutical policy and pricing. As the pharmaceutical market continues to expand, a number of pharmaceutical pricing strategies have been employed to control drug expenditures. The book explores this phenomenon further and willserve a valuable resource for policy makers, funders, social insurance institutions and drug companies. About the author Zaheer-Ud-Din Babar, PhD is the Head of Pharmacy Practice at the School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. A pharmacist by training and a PhD in pharmaceutical policy, Dr Babar is a recipient of the prestigious Research Excellence Award from the University of Auckland. His research program covers areas related to pharmaceutical policy and practice, encompassing access to and affordability of medicines, issues related to medicine pricing and pharmacoeconomics. Dr Babar has delivered invited lectures at Boston University School of Public Health, Harvard Medical School, the Austrian Health Institute and the Universities of Reading and Kingston. He has also acted as a consultant for the World Health Organization, Health Action International, the International Union against Tuberculosis and Lung Disease, the International Pharmaceutical Federation (FIP) and the Pharmaceutical Management Agency of New Zealand in the area of medicines pricing and policies. Dr Babar is the Editor in Chief of the Journal of Pharmaceutical Policy and Practice, www.joppp.org and can be reached at z.babar@auckland.ac.nz.
650 0 $a Drugs $x Prices. $3 821594
650 0 $a Pharmaceutical policy. $3 630828
650 0 $a Drugs $x Marketing. $3 613432
650 1 4 $a Economics/Management Science. $3 890844
650 2 4 $a Health Economics. $3 820895
700 1 $a Babar, Zaheer-Ud-Din. $3 2133282
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-12169-7
950 $a Business and Economics (Springer-11643)